Low Serum miR-607 Level as a Potential Diagnostic and Prognostic Biomarker in Patients of Pancreatic Ductal Adenocarcinoma: A Preliminary Study

Table 1

Relation between miR-607 expression and clinicopathological characteristics of PDAC patients.

Variables	Number	miR-607 expression
		Low (n = 25, %)	High (n = 25, %)
Age (years)				0.087
<60	22	8 (16%)	14 (28%)
≥60	28	17 (34%)	11 (22%)
Gender				0.083
Male	30	12 (24%)	18 (36%)
Female	20	13 (26%)	7 (14%)
Tumor size (cm)				0.355
<3	15	9 (18%)	6 (12%)
≥3	35	16 (32%)	19 (38%)
Tumor differentiation				0.771
Well - moderate	19	10 (20%)	9 (18%)
Poor	31	15 (30%)	16 (32%)
Clinical stage				0.136
I-II	17	6 (12%)	11 (22%)
III-IV	33	19 (38%)	14 (28%)
T Stage				0.152
T1-T2	21	13 (26%)	8 (16%)
T3-T4	29	12 (24%)	17 (34%)
Lymphatic metastasis				0.002
Negative	14	2 (4%)	12 (24%)
Positive	36	23 (46%)	13 (26%)
Perineural invasion				0.004
Negative	22	6 (12%)	16 (32%)
Positive	28	19 (38%)	9 (18%)
Liver metastasis				0.018
Negative	45	20 (40%)	25 (50%)
Positive	5	5 (10%)	0 (0%)
CEA level (ng/mL)				0.774
<5	21	10 (20%)	11 (22%)
≥5	29	15 (30%)	14 (28%)
CA19-9 level (U/mL)				0.333
<35	13	8 (16%)	5 (10%)
≥35	37	17 (34%)	20 (40%)

PDAC: pancreatic ductal adenocarcinoma.